

Report, Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report, Stock No. 017-001-00473-1) referenced in the "INTRODUCTION" through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: January 27, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-2571 Filed 2-2-98; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Revised Diphtheria, Tetanus, and Pertussis (DTD/DTaP/DT) Vaccine Information Materials; Amendment

A notice published in the **Federal Register** on January 9, 1998, [63 FR 1730]. The notice is amended as follows:

On page 1733, first column, under number 9. After "Visit the CDC website at <http://www.cdc.gov/nip>" line and before "DTP/DTaP/DT****" add the following:

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Immunization Program

All other information and requirements of the January 9, 1998, notice remain the same.

Dated: June 27, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-2570 Filed 2-2-98; 8:45 am]

BILLING CODE 4163-18-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Anti-Infective Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on February 19, 1998, 8 a.m. to 5 p.m., and on February 20, 1998, 8:30 a.m. to 2 p.m.

Location: Gaithersburg Hilton, Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Ermona B. McGoodwin or Danyiel A. D'Antonio, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12530. Please call the Information Line for up-to-date information on this meeting.

Agenda: On February 19, 1998, the committee will discuss new drug applications (NDA's) 50-747 and 50-748 quinupristin/dalfopristin (Synercid®, Rhone-Poulenc Rorer Pharmaceuticals, Inc.) for use in the treatment of vancomycin-resistant *Enterococcus faecium* (VREF) infections, complicated skin and skin structure infections, community-acquired pneumonia, and hospital-acquired (nosocomial) pneumonia. On February 20, 1998, the committee will meet in closed session to permit discussion and review of trade secret and/or confidential information.

Procedure: On February 19, 1998, from 8 a.m. to 5 p.m. the meeting will be open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 13, 1998. Oral presentations from the public will be scheduled between approximately 1:30 p.m. and 2:30 p.m. on February 19, 1998. Time allotted for each presentation may be limited. Those desiring to make formal presentations should notify the contact person before February 13, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 20, 1998, from 8:30 a.m. to 2 p.m. the meeting will be closed to permit discussion and review of trade secret and/or confidential information. (5 U.S.C. 552b(c)(4)). The investigational

new drug (IND) and Phase I and II drug products in process will be presented.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-2577 Filed 2-2-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Drug Abuse Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Drug Abuse Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on February 19, 1998, 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn, Versailles Ballrooms III and IV, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4090, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12535. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss the scientific evidence for initiating a scheduling action for ULTRAM® (tramadol hydrochloride), R. W. Johnson Pharmaceutical Research Institute, under the Controlled Substances Act. The committee will also evaluate the effectiveness of the independent steering committee in detecting, moderating, and preventing the physical dependence and abuse of ULTRAM® and make suggestions for improving the surveillance of its misuse.

Procedure: On February 19, 1998, from 8:30 a.m. to 3:45 p.m., the meeting is open to the public. Interested persons may present data, information, or views,